JAK Inhibitors and NAK Inhibitors for COVID-19 Treatment JAK and NAK inhibitors are classified as DMARDs used for the treatment of psoriasis, inflammatory bowel disease (IBD), arthritis and many other conditions. Several hypothesis claim JAK and NAK inhibitors can play a significant role in treatment of COVID-19. According to autopsy findings of COVID-19 patients, hypercoagulation and thrombosis are severe complications of COVID-19 pneumonia. To combat this complication, JAK and NAK inhibitors can be employed. Currently, research clinical trials are being conducted to conclude the use of these drugs in the treatment of COVID-19.